A61K31/702

COMPOSITIONS COMPRISING AT LEAST ONE N-ACETYLATED AND AT LEAST ONE FUCOSYLATED OLIGOSACCHARIDE FOR USE IN THE PROMOTION OF DIGESTIVE CAPACITY IN INFANTS AND YOUNG CHILDREN

This invention relates to compositions for use in the promotion of the development and/or of the growth of the surface area of the small intestine and in the associated improvement of the digestive capacity in an infant or in a young child.

NOVEL COMPOSITION FOR REDUCING STRESS DISORDERS

The present invention concerns an edible ingredient providing a short chain fatty acid ratio in the gut such that acetate is n a ratio ranging from 70 to 80, propionate is in a ratio ranging from 2 to 8, butyrate is in a ratio ranging from 20 to 25 and wherein the sum of individual ratios for acetate, propionate and butyrate equals 100 to food compositions comprising such edible ingredient for use in the attenuation of stress response and/or prevention of chronic stress and of conditions thereby associated.

NOVEL COMPOSITION FOR REDUCING STRESS DISORDERS

The present invention concerns an edible ingredient providing a short chain fatty acid ratio in the gut such that acetate is n a ratio ranging from 70 to 80, propionate is in a ratio ranging from 2 to 8, butyrate is in a ratio ranging from 20 to 25 and wherein the sum of individual ratios for acetate, propionate and butyrate equals 100 to food compositions comprising such edible ingredient for use in the attenuation of stress response and/or prevention of chronic stress and of conditions thereby associated.

METHODS AND COMPOSITIONS TO PREVENT AND TREAT INFLAMMATION AND ALLERGIC REACTIONS
20230081146 · 2023-03-16 ·

The disclosure relates to compositions and methods for treating infection, allergic reactions, colitis, IBD, contact dermatitis, psoriasis, atopic dermatitis, graft vs. host disease and disorders and other disease and disorders comprising dendritic cell activation as well as compositions and method to improve allergen sensitization.

METHODS AND COMPOSITIONS TO PREVENT AND TREAT INFLAMMATION AND ALLERGIC REACTIONS
20230081146 · 2023-03-16 ·

The disclosure relates to compositions and methods for treating infection, allergic reactions, colitis, IBD, contact dermatitis, psoriasis, atopic dermatitis, graft vs. host disease and disorders and other disease and disorders comprising dendritic cell activation as well as compositions and method to improve allergen sensitization.

Method for promoting growth of <i>Akkermansia muciniphila </i>using <i>musa </i>ferments
11478525 · 2022-10-25 · ·

Provided is a method of promoting the growth of Akkermansia muciniphila, including contacting A. muciniphila with an effective amount of a prebiotic composition including a Musa ferment. Also provided is a prebiotic composition including a Musa ferment. The prebiotic composition promotes the growth of A. muciniphila in the intestine, and reduces the body weight, fat percentage, waist circumference, and hip circumference of obese individuals.

Method for promoting growth of <i>Akkermansia muciniphila </i>using <i>musa </i>ferments
11478525 · 2022-10-25 · ·

Provided is a method of promoting the growth of Akkermansia muciniphila, including contacting A. muciniphila with an effective amount of a prebiotic composition including a Musa ferment. Also provided is a prebiotic composition including a Musa ferment. The prebiotic composition promotes the growth of A. muciniphila in the intestine, and reduces the body weight, fat percentage, waist circumference, and hip circumference of obese individuals.

Human milk oligosaccharides for treating migraine
11602545 · 2023-03-14 · ·

The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing or treating migraine in a human.

Human milk oligosaccharides for treating migraine
11602545 · 2023-03-14 · ·

The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing or treating migraine in a human.

COMBINATION OF T-CELL CHECKPOINT INHIBITORS WITH INHIBITORS OF E-SELECTIN OR CXCR4, OR WITH HETEROBIFUNCTIONAL INHIBITORS OF BOTH E-SELECTIN AND CXCR4
20230127765 · 2023-04-27 · ·

Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C-X-C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.